Skip to content

Immunovant, Inc. IMVT Change in Other Assets

Change in Other Assets at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$1.05M+1,152%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$1.03M-27.7%
Roivant Sciences logo
Roivant SciencesROIV
$1.85M-15.3%
IQVIA logo
IQVIAIQV
-$54.5M-3,014%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentAssets.

The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunovant, Inc.'s change in other assets?
Immunovant, Inc. (IMVT) reported change in other assets of -$1.3M in Q1 2026.
How has Immunovant, Inc.'s change in other assets changed year-over-year?
Immunovant, Inc.'s change in other assets decreased by 767.2% year-over-year, from $195K to -$1.3M.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.